The present invention relates to novel antibody frameworks with advantageous properties. For example, this invention relates to novel chimeric human antibody light chain frameworks, comprising framework regions I to III from Vκ and framework region IV from Vλ, with advantageous properties, such as high stability and reduced aggregation propensity.Cette invention concerne de nouvelles structures d'anticorps ayant des propriétés avantageuses.